Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy

Description

This study is to determine if low level vagus nerve stimulation will lead to improvement in heart function, heart rate variation, and in the levels of certain chemical markers of inflammation in study participants' blood.

Conditions

Breast Cancer, Lymphoma

Talk to us

Study Overview

On this page

Study Details

Study overview

This study is to determine if low level vagus nerve stimulation will lead to improvement in heart function, heart rate variation, and in the levels of certain chemical markers of inflammation in study participants' blood.

Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy: A First in Human Randomized Pilot Study. Neuromodulation in Cancer Study (OU-SCC-NCAN)

Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy

Condition
Breast Cancer
Intervention / Treatment

-

Contacts and Locations

Oklahoma City

Stephenson Cancer Center, Oklahoma City, Oklahoma, United States, 73104

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Patients (\>50 years) with breast cancer or lymphoma, who have received anthracycline-based therapy (a cumulative dose of ≥ 200 mg/m2 Doxorubicin or bioequivalent dose of other anthracyclines) and/or HER2 antagonists within the last 60-90 days and have \>= 1 of following additional criteria:
  • * previous chest radiation,
  • * type 2 diabetes mellitus,
  • * hypertension,
  • * current smoking,
  • * obesity (BMI ≥ 30),
  • * previous myocardial infarction or
  • * established atherosclerotic heart disease.
  • 1. atrial paced rhythm,
  • 2. history of seizure currently on treatment,
  • 3. history of vasovagal syncope,
  • 4. end stage liver or kidney disease.

Ages Eligible for Study

50 Years to 99 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Oklahoma,

Tarun W. Dasari, MD, MPH, PRINCIPAL_INVESTIGATOR, University of Oklahoma

Study Record Dates

2026-09